policy

Biotech By Damian Garde and Nicholas Florko

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

First Opinion By Sevahn Vorperian and Stephen Quake

The PASTEUR Act can help win the war against superbugs

Politics By Nicholas Florko

Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs

D.C. Diagnosis By Rachel Cohrs

The lonely quest to create a commission to investigate Covid-19

First Opinion By David Blumenthal

Restore a better balance to public-private funding of biomedical research

Politics By Megan Molteni

California could become first state to mandate biosecurity screening by mail-order DNA companies

First Opinion By Parsa Erfani, Lawrence O. Gostin, and Vanessa Kerry

Beyond a symbolic gesture: What’s needed to turn the IP waiver into Covid-19 vaccines

First Opinion By Jonathan Doh

Make drug companies partners — not adversaries — to expand global Covid-19 vaccine access

Opinions+ By John Freedman

The many benefits of expanding the reach of state all-payer claims databases

Health Tech By Andrew Joseph

Former Google CEO Schmidt says AI ‘will have its biggest impact’ in health care

Hospitals By Rachel Cohrs

HHS plans to open up billions in hospital Covid-19 grants in coming weeks

Politics By Rachel Cohrs

Top Senate Democrat heads back to drawing board on drug pricing

Politics By Lev Facher

Do public health officials need to be political activists? A fight over an HIV crisis renews the question

Health By Alicia Diaz

Door knocking works to get information to immigrant communities. Why aren’t more places using it for Covid-19?

Politics By Nicholas Florko and Rachel Cohrs

Worried drug pricing reform might be left behind, Democrat pushes Biden to make clear his support

First Opinion By Joe Lonsdale

FTC’s challenge to Illumina’s vertical merger with Grail is all wrong

Exclusive By Nicholas Florko

Biden officials met privately with 3M, AmerisourceBergen, PhRMA, and more to debate shoring up the national stockpile 

Opinions+ By Patrick McLaughlin and Tyler Richards

The FDA should embrace remote and automated drug inspection technology

Politics By Rachel Cohrs

The lobbying juggernaut the American Hospital Association is losing its top advocate at a critical moment for the industry

Politics By Nicholas Florko

Hints emerge about a key Senate committee’s plans for health care

First Opinion By Ethan Dmitrovsky

Rethinking triage in an era of vaccine nationalism

First Opinion Podcast By Patrick Skerrett

Listen: Two addiction specialists debunk the myth of ‘excited delirium’ used in police encounters

Politics By Nicholas Florko

PhRMA chief talks strategy — and he’s surprisingly optimistic about drug pricing reform

Opinions+ By Pierre Bourdage

Three steps toward creating a functioning U.S. biosimilars market

First Opinion By Michael Carney

Make it easier for employers to help get America vaccinated